Sanjeev Choubey
Angles University Foundation, Philippines
Posters & Accepted Abstracts: J Diabetes Metab
It is well known that type 2 diabetes is associated with a progression with an inevitable progression of beta cell dysfunction, in the absence of established methods to permanently protect the beta cells; the only clinical option available to physician is to intensify therapeutic measures at each stage of diabetes. Therefore, when one or more oral hypoglycemic agents are not available to maintain A1c targets, basal insulin is often added, as this is an option endorsed by the diabetes association across the world. However, given the progressive nature of type 2 diabetes, the A1c continue to rise and this requires the addition of prandial insulins. The choice that physician often face at this point may be divided into 5. Is there a possibility of adding a single prandial insulin injection, i.e a basalplus regimen or a single injection co-formulation based regimen? A second option is to switch to a premix or a co-formulation based regime, third option is the clinician could consider the optimization of the existing oral drug regime. A fourth option is the institution of basal regimen. A fifth option is to add an incretin based injectable regimen. This article will discuss the pros and cons of the various options in the management of type 2 diabetes.
Email: sanjeevchoubey@outlook.com
